WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 510284
CAS#: 1226895-20-0
Description: ATB-346 is anti- inflammatory agent, which is structurally an analogue of naproxen. ABT-346 exhibits anti-inflammatory properties similar to naproxen, but with substantially reduced gastrointestinal toxicity. ATB-346 suppressed colonic prostaglandin synthesis and whole blood thromboxane synthesis as effectively as naproxen, but did not induce any gastrointestinal injury. ATB-346 exerts superior chemopreventive effects to those of naproxen, while sparing the gastrointestinal tract of the injury normally associated with use of the parent drug. ATB-346 may therefore be an attractive agent for chemoprevention of colon cancer, and possibly of cancers in other tissues.
MedKoo Cat#: 510284
Name: ATB-346
CAS#: 1226895-20-0
Chemical Formula: C21H19NO3S
Exact Mass: 365.10856
Molecular Weight: 365.44
Elemental Analysis: C, 69.02; H, 5.24; N, 3.83; O, 13.13; S, 8.77
ABT-346, purity > 98%, is in stock. The same day shipping after order is received.
Synonym: ATB346; ATB-346; ATB 346.
IUPAC/Chemical Name: 4-carbamothioylphenyl 2-(6-methoxynaphthalen-2-yl)propanoate.
InChi Key: YCNMAPLPQYQJFC-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H19NO3S/c1-13(21(23)25-18-8-5-14(6-9-18)20(22)26)15-3-4-17-12-19(24-2)10-7-16(17)11-15/h3-13H,1-2H3,(H2,22,26)
SMILES Code: CC(C1=CC=C2C=C(OC)C=CC2=C1)C(OC3=CC=C(C(N)=S)C=C3)=O
The following data is based on the product molecular weight 365.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Elsheikh W, Blackler RW, Flannigan KL, Wallace JL. Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. Nitric Oxide. 2014 Apr 18. pii: S1089-8603(14)00204-3. doi: 10.1016/j.niox.2014.04.006. [Epub ahead of print] PubMed PMID: 24747869.
2: Ekundi-Valentim E, Mesquita FP, Santos KT, de Paula MA, Florenzano J, Zanoni CI, Rodrigues L, de Nucci G, Teixeira SA, Ferreira HH, Wallace JL, Costa SK, Muscará MN. A comparative study on the anti-inflammatory effects of single oral doses of naproxen and its hydrogen sulfide (H2S)-releasing derivative ATB-346 in rats with carrageenan-induced synovitis. Med Gas Res. 2013 Nov 16;3(1):24. doi: 10.1186/2045-9912-3-24. PubMed PMID: 24237604; PubMed Central PMCID: PMC3843537.
3: Campolo M, Esposito E, Ahmad A, Di Paola R, Wallace JL, Cuzzocrea S. A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury. FASEB J. 2013 Nov;27(11):4489-99. doi: 10.1096/fj.13-234716. Epub 2013 Jul 30. PubMed PMID: 23901068.
4: Blackler R, Syer S, Bolla M, Ongini E, Wallace JL. Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One. 2012;7(4):e35196. doi: 10.1371/journal.pone.0035196. Epub 2012 Apr 9. PubMed PMID: 22496907; PubMed Central PMCID: PMC3322164.
5: Wallace JL, Caliendo G, Santagada V, Cirino G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol. 2010 Mar;159(6):1236-46. doi: 10.1111/j.1476-5381.2009.00611.x. Epub 2010 Feb 1. PubMed PMID: 20128814; PubMed Central PMCID: PMC2848928.
